Clinic of Otolaryngology, Catholic University of the Sacred Heart, Rome, Italy.
Acta Otorhinolaryngol Ital. 2010 Apr;30(2):87-93.
This study aimed to evaluate audiological and vestibular involvement in Fabry disease and the effects of enzyme replacement therapy with human alpha-galactosidase A. The study population comprised 20 patients (11 males, 9 females) aged 15-69 years (mean 39.7). Patients underwent a complete clinical and instrumental evaluation before starting and during enzyme replacement therapy. Median follow-up was 51.5 months (range 25-73). Nine patients (45%) complained of hearing symptoms (hearing loss, tinnitus); for six of them the onset and/or progression of the hearing loss were sudden. Vertigo or dizziness was reported by 6 patients (30%). Audiological evaluation showed a sensorineural hearing loss in 18 ears (45%; 10 in male patients, 8 in females). The hearing thresholds for 0.5, 1, 2 and 4 kHz frequencies ranged from 10 to 65 dB HL. Hearing loss was unilateral in 8 cases (40%; 4 in male patients, 4 in females). Also high frequency hearing loss for 4 and 8 kHz was evaluated. No signs of retro-cochlear lesions were observed by means of otoacoustic emissions and auditory brainstem response. Vestibular examinations showed a functional impairment in 7 ears (17.5%, all male patients). During enzyme replacement therapy the auditory function showed some degrees of worsening but no significant changes were observed at statistical analysis. In conclusion involvement of the inner ear is common in men and women with Fabry disease. In this study, a high incidence of cochlear hearing loss was found, which was typically unilateral and showed onset and/or progression by sudden episodes. Vascular or hydropic mechanisms could be hypothesized to explain audiological findings. Vestibular involvement showed a lower incidence and different pattern, thus suggesting that several patho-physiological mechanisms could play a role in determining inner ear damage in Fabry disease. Results obtained show that enzyme replacement therapy may stabilize hearing function; however, further studies on the physiopathology of the inner ear damage are needed.
本研究旨在评估法布里病的听力和前庭功能障碍,以及人α-半乳糖苷酶 A 酶替代治疗的效果。研究人群包括 20 名 15-69 岁(平均 39.7 岁)的患者(11 名男性,9 名女性)。在开始和进行酶替代治疗期间,患者接受了完整的临床和仪器评估。中位随访时间为 51.5 个月(范围 25-73)。9 名患者(45%)有听力症状(听力损失、耳鸣);其中 6 名患者的听力损失是突发性的开始和/或进展。6 名患者(30%)报告有眩晕或头晕。听力评估显示 18 只耳朵(45%;10 只在男性患者中,8 只在女性患者中)有感觉神经性听力损失。0.5、1、2 和 4 kHz 频率的听力阈值范围为 10-65 dB HL。8 例(40%;4 例在男性患者中,4 例在女性患者中)为单侧听力损失。还评估了 4 和 8 kHz 的高频听力损失。耳声发射和听觉脑干反应均未观察到耳蜗后病变的迹象。前庭检查显示 7 只耳朵(17.5%,均为男性患者)存在功能障碍。在酶替代治疗期间,听觉功能有一定程度的恶化,但在统计学分析中未观察到显著变化。总之,法布里病患者的内耳受累常见于男性和女性。在本研究中,发现了较高的耳蜗听力损失发生率,通常为单侧,且突发性发作和/或进展。血管或水肿机制可被假设为解释听力结果的原因。前庭受累发生率较低,模式不同,因此提示多种病理生理机制可能在法布里病内耳损伤中起作用。研究结果表明,酶替代治疗可能稳定听力功能;然而,还需要进一步研究内耳损伤的病理生理学。